Akari Therapeutics PLC (AKTX) Short Interest Update

Akari Therapeutics PLC (NASDAQ:AKTX) was the target of a large decrease in short interest in the month of March. As of March 29th, there was short interest totalling 224,405 shares, a decrease of 82.7% from the March 15th total of 1,298,522 shares. Currently, 1.6% of the shares of the company are sold short. Based on an average daily volume of 780,733 shares, the days-to-cover ratio is currently 0.3 days.

An institutional investor recently bought a new position in Akari Therapeutics stock. Virtu Financial LLC acquired a new position in shares of Akari Therapeutics PLC (NASDAQ:AKTX) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 39,864 shares of the biopharmaceutical company’s stock, valued at approximately $143,000. Virtu Financial LLC owned approximately 0.26% of Akari Therapeutics as of its most recent SEC filing. 13.88% of the stock is currently owned by hedge funds and other institutional investors.

AKTX stock traded up $0.08 on Friday, reaching $3.78. The company’s stock had a trading volume of 81,088 shares, compared to its average volume of 1,546,859. The firm has a market capitalization of $59.94 million, a price-to-earnings ratio of -22.24 and a beta of -3.75. Akari Therapeutics has a 52 week low of $1.56 and a 52 week high of $9.20.

Akari Therapeutics (NASDAQ:AKTX) last issued its quarterly earnings results on Tuesday, April 23rd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter. On average, sell-side analysts forecast that Akari Therapeutics will post -2 EPS for the current fiscal year.

A number of analysts have recently weighed in on AKTX shares. ValuEngine upgraded Akari Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, March 14th. B. Riley set a $7.00 price target on Akari Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, March 19th. Finally, Zacks Investment Research raised Akari Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a report on Friday, April 26th.

ILLEGAL ACTIVITY NOTICE: “Akari Therapeutics PLC (AKTX) Short Interest Update” was originally published by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.baseballdailydigest.com/news/2019/05/05/short-interest-in-akari-therapeutics-plc-aktx-decreases-by-82-7.html.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome.

Featured Story: What is the Moving Average Convergence Divergence (MACD) oscillator?

Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.